Hello.

My name is Tom Fife-Shaw, Research Director at Ipsos Corporate Reputation.

I'm delighted to introduce the third wave of the ABPI Ipsos Pharma Reputation Index.

Since 2021, we've conducted research with the public, healthcare professionals, and parliamentarians to understand what they know about pharmaceutical companies operating in the UK and what they think and feel about them.

We've collected quant key performance indicators to track the sector's reputation over time at a high level.

Is it known? Is it liked and is it trusted? And how does that compare with other sectors?

We've also explored perceptions of the work pharma companies do, their intentions and how they are seen to behave in order to understand what might explain those KPIs.

The topics and themes we've explored in this work are often complex.

Using focus groups and indepth interviews, we've augmented our statistics with nuanced granular insights to get a deeper understanding of how people have formed their views of pharma companies.

That is, the information, the experiences, the assumptions, the memories and the feelings that underpin their points of view.

As you'll see in our index, we know that citizens and stakeholders alike tend to agree that the sector makes safe and effective medicines that people need using cutting edge technology.

Indeed, the idea of innovation is often a top of mind association with pharma for most audiences.

Now, people remain positive about the sector's actions during the pandemic.

And with that in mind, it is perhaps unsurprising that seven in ten members of the public trust pharmaceutical companies operating in the UK to be willing to tackle future pandemics.

But we also know that despite the heightened profile of pharma in recent years, it isn't really any better known or particularly well understood, sometimes even by the stakeholders who might come into contact with pharma companies more often.

In the absence of detailed knowledge, there is sometimes an assumption that the sector lacks transparency.

This, in turn then colours their views of big, complex and emotive topics such as drug pricing or access to medicines and vaccines.

This index provides some food for thought for the sector on how it might capitalise on its reputational strengths, but also what it might need to do in order to address areas of relative reputational weakness.

How can it best demonstrate the value of its medical innovations and the value it brings to the UK economy and society?

And importantly, what might get people's attention?

We hope you find this index a useful resource that piques your interest.

If you have any questions, comments or suggestions, suggestions for future measurement, we'd love to hear from you. Thank you.